JOP20220050A1 - مركبات بيرازول، صياغات منها وطريقة لاستخدام المركبات و/ أو صياغات - Google Patents

مركبات بيرازول، صياغات منها وطريقة لاستخدام المركبات و/ أو صياغات

Info

Publication number
JOP20220050A1
JOP20220050A1 JOP/2022/0050A JOP20220050A JOP20220050A1 JO P20220050 A1 JOP20220050 A1 JO P20220050A1 JO P20220050 A JOP20220050 A JO P20220050A JO P20220050 A1 JOP20220050 A1 JO P20220050A1
Authority
JO
Jordan
Prior art keywords
formulations
compounds
composition
compound
disclosed
Prior art date
Application number
JOP/2022/0050A
Other languages
English (en)
Inventor
Yan Chen
Ihab Darwish
Vanessa Taylor
Somasekhar Bhamidipati
Matt Duan
lu Chou
Simon Shaw
Dazhong Fan
Zhushou Luo
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of JOP20220050A1 publication Critical patent/JOP20220050A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بتجسيدات مركب بيرازول وفقاً للصيغة I. يتم الكشف أيضاً عن تركيبات تشتمل على المركب، وطريقة لتحضير التركيبة. يمكن أن تشتمل التركيبة على مادة حاملة، مثل بوليمر و/ أو تركيبة يمكن أن تكون عبارة عن صياغة مجففة بالرش. يتم الكشف أيضاً عن طريقة لاستخدام المركب و/ أو التركيبة. يمكن أن يكون المركب و/ أو التركيبة مفيدين لتثبيط بروتين IRAK و/ أو لتحسين، علاج و/ أو الوقاية من مرض أو حالة مرضية مرتبط بـ IRAK في خاضع.
JOP/2022/0050A 2019-08-30 2020-08-28 مركبات بيرازول، صياغات منها وطريقة لاستخدام المركبات و/ أو صياغات JOP20220050A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962894547P 2019-08-30 2019-08-30
PCT/US2020/048528 WO2021041898A1 (en) 2019-08-30 2020-08-28 Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations

Publications (1)

Publication Number Publication Date
JOP20220050A1 true JOP20220050A1 (ar) 2023-01-30

Family

ID=72473975

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0050A JOP20220050A1 (ar) 2019-08-30 2020-08-28 مركبات بيرازول، صياغات منها وطريقة لاستخدام المركبات و/ أو صياغات

Country Status (18)

Country Link
US (3) US11370787B2 (ar)
EP (1) EP4003990A1 (ar)
JP (1) JP2022545542A (ar)
KR (1) KR20220054626A (ar)
CN (1) CN114364674A (ar)
AR (1) AR119857A1 (ar)
AU (1) AU2020335903A1 (ar)
BR (1) BR112022003564A2 (ar)
CA (1) CA3152264A1 (ar)
CO (1) CO2022002993A2 (ar)
CR (1) CR20220085A (ar)
EC (1) ECSP22014379A (ar)
IL (1) IL290882A (ar)
JO (1) JOP20220050A1 (ar)
MX (1) MX2022002292A (ar)
PE (1) PE20220970A1 (ar)
TW (1) TW202122393A (ar)
WO (1) WO2021041898A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545542A (ja) * 2019-08-30 2022-10-27 ライジェル ファーマシューティカルズ， インコーポレイテッド ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法
US20220288047A1 (en) * 2021-03-03 2022-09-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202346291A (zh) * 2022-03-23 2023-12-01 美商雷傑製藥公司 作為ｉｒａｋ抑制劑的嘧啶—２—基—吡唑化合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
ATE107176T1 (de) 1989-12-04 1994-07-15 Searle & Co System zur transdermalen albuterol applikation.
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2006070202A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives having kinase modulating activity
WO2009054468A1 (ja) 2007-10-24 2009-04-30 Astellas Pharma Inc. アゾールカルボキサミド化合物又はその塩
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
US8987309B2 (en) 2009-04-17 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles
EP2243481A1 (en) 2009-04-24 2010-10-27 PamGene B.V. Irak kinase family as novel drug target for Alzheimer
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
ES2601004T3 (es) 2010-04-07 2017-02-13 F. Hoffmann-La Roche Ag Compuestos pirazol-4-il-heterociclil-carboxamida y métodos de uso
EP2640708A1 (en) 2010-11-19 2013-09-25 Ligand Pharmaceuticals Inc. Heterocycle amines and uses thereof
EP2561102A1 (en) 2010-12-02 2013-02-27 Katholieke Universiteit Leuven K.U. Leuven R&D Irak-related interventions and diagnosis
CA2822166C (en) 2010-12-20 2019-10-29 Merck Serono S.A. Indazolyl triazole derivatives as irak inhibitors
EP3239154A1 (en) 2011-01-10 2017-11-01 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP2674423A4 (en) 2011-02-09 2014-07-30 Nissan Chemical Ind Ltd PYRAZONE DERIVATIVE AND PESTICIDES
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
TWI570117B (zh) 2011-09-27 2017-02-11 赫孚孟拉羅股份公司 吡唑－４－基－雜環甲醯胺化合物及使用方法
CA2863259A1 (en) 2012-01-10 2013-07-18 Nimbus Iris, Inc. Irak inhibitors and uses thereof
DK2900657T3 (da) 2012-09-26 2020-05-04 Hoffmann La Roche Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
US9586948B2 (en) 2012-10-08 2017-03-07 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
BR112015018663A2 (pt) 2013-02-07 2017-07-18 Merck Patent Gmbh derivados de piridazinona-amidas
JP6267729B2 (ja) 2013-02-07 2018-01-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 大環状ピリダジノン誘導体
CN106068264B (zh) 2014-01-09 2019-06-21 默克专利有限公司 嘧啶吡唑基衍生物及其作为irak抑制剂的用途
CA2964982C (en) 2014-11-20 2022-07-05 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof
SG11201707752SA (en) 2015-04-22 2017-11-29 Rigel Pharmaceuticals Inc Pyrazole compounds and method for making and using the compounds
CN110099899B (zh) * 2016-10-26 2024-01-02 里格尔药品股份有限公司 用作irak抑制剂的噁唑衍生物及其制备方法
JP2022545542A (ja) * 2019-08-30 2022-10-27 ライジェル ファーマシューティカルズ， インコーポレイテッド ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法

Also Published As

Publication number Publication date
US20210061798A1 (en) 2021-03-04
IL290882A (en) 2022-04-01
TW202122393A (zh) 2021-06-16
WO2021041898A1 (en) 2021-03-04
PE20220970A1 (es) 2022-06-10
US11370787B2 (en) 2022-06-28
AU2020335903A1 (en) 2022-03-24
AR119857A1 (es) 2022-01-19
CR20220085A (es) 2022-04-19
CO2022002993A2 (es) 2022-04-19
CN114364674A (zh) 2022-04-15
JP2022545542A (ja) 2022-10-27
BR112022003564A2 (pt) 2022-05-17
MX2022002292A (es) 2022-06-02
US20220306620A1 (en) 2022-09-29
EP4003990A1 (en) 2022-06-01
ECSP22014379A (es) 2022-05-31
CA3152264A1 (en) 2021-03-04
US20230399326A1 (en) 2023-12-14
KR20220054626A (ko) 2022-05-03

Similar Documents

Publication Publication Date Title
MX2022002292A (es) Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones.
CR20210201A (es) Nuevos compuestos antihelmínticos
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
UA100526C2 (ru) Способ и композиция для обработки семян
MX2020001404A (es) Dihidrooxadiazinonas.
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
MX2020011873A (es) Nuevos derivados de quinolina.
MX2023003264A (es) Inhibidores de cdk y su uso como productos fármaceuticos.
WO2019241802A3 (en) Methods of inhibiting proliferative cells
AU2020258568A8 (en) CD73 inhibitors
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
EA201691962A1 (ru) Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2
MX2021006724A (es) Compuestos de halo-alilamina y uso de los mismos.
MX2022001690A (es) Compuestos deuterados para usarse en el tratamiento del cancer.
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
MX2022013066A (es) Formulacion estable.
MX2023012187A (es) Derivados de fosforo como nuevos inhibidores de sos1.
MX2020010834A (es) Formulacion solida de mezclas insecticidas.
MX2022010219A (es) Compuestos heterociclicos de heteroarilo y usos de los mismos.
MX2023003443A (es) Inhibidores de la proteína cinasa alfa 1 y métodos de uso.
MX2021009033A (es) Sales de sulcardina.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
ZA202309924B (en) Amarouciaxanthin a esters and uses thereof
MX2023000198A (es) Inhibidores de atr y usos de estos.